drugset
drugset / Trial / NCT00220116

Phase II Trial Assessing Efficacy and Toxicity of Capecitabine and Oxaliplatin in the Treatment of Colorectal Cancer

NCT00220116 ↗

Phase 2 Completed 172 enrolled Royal Marsden NHS Foundation Trust
Non-randomizedParallel-groupOpen-labelTreatment

Summary

To assess the efficacy and safety of the combination of capecitabine and oxaliplatin in the 1st, 2nd or subsequent line treatment of metastatic colorectal cancer, and also in the neo-adjuvant and adjuvant setting of resectable metastases. Primary Endpoint: Objective response rates Secondary Endpoints: Treatment related toxicity Progression free survival (If not resected) Disease free Survival (From metastastectomy, if resected) Overall Survival 60 Day all cause mortality Number undergoing liver resections/curative resection (Ro) rate

Timeline

Start
2002-08
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule — —
Subject Oxaliplatin Small molecule — —

Indications

colorectal cancer